Key Takeaways
- Revenue surged 31% on exports, domestic hit by monsoon: International business drove the headline number while erratic rainfall suppressed domestic spraying, volumes, and pest incidence, creating a two-speed quarter.
- Margins held flat despite raw material squeeze: EBITDA margin inched up 30 bps YoY to 12.4%, but PBT margins fell on higher depreciation and lower other income; international profitability was pinched because price hikes could not fully cover raw material cost jumps.
- Working capital stretched from both sides: Domestic receivables lengthened on monsoon-driven liquidation stress and a pullback in payment incentives; international receivables rose after the company stopped discounting for one key customer.
- High-cost inventory overhang is clearing: Management worked down high-cost inventory by accepting lower margins on liquidation, and now says the worst of that drag is behind them.
- What to watch next quarter: Whether the Rabi season delivers the promised pickup, how much agrochemical inventory rolls over into H2 and pressures liquidation, and whether international pricing pressure from Brazil and Southeast Asia intensifies.
Domestic Business: A Monsoon-Driven Miss
- Erratic rainfall broke the spraying cycle: Excess rains in Maharashtra, Gujarat, and Telangana damaged cotton crops and led farmers to skip sprays; key paddy-growing states in the East saw deficit rains and declining sown area, further compressing volumes.
- Growth was price-led, not volume-led: Domestic revenue growth came almost entirely from carry-forward price increases taken earlier to offset input costs; underlying volumes were largely flat.
- Herbicides were the lone bright spot: Products like Tata Panida, Pepe, Honcho, and Riceup registered double-digit growth, while insecticides and fungicides sales remained muted across regions.
- Crop Nutrition bucked the trend: The category, spanning biologicals, soil health products, water-soluble fertilizers, and micronutrients, grew nearly 30% and is being positioned as a future growth engine with a target of at least 20% growth this year.
- Inventory rollover looms over H2: Management assesses that a considerable amount of unsold inventory from all agrochemical companies will roll into the second half, creating pressure on liquidation just as the industry tries to place fresh Rabi stock.
Sanjiv Lal: "Last year, we have seen a fairly large roll-over of inventory into H2. And it is our assessment that there's going to be a lot of rollover of inventory of all agrochemical companies into H2 as well. So there is going to be a considerable amount of pressure in terms of liquidation of agrochemicals in the market."
International Business: Strong Volumes, Weaker Pricing
- Volume-led growth with elevated utilization: Pendimethalin, Kresoxim Methyl, and Acephate plants ran at high utilization rates, and Metribuzin sales showed early signs of a pickup after prior-quarter inventory normalization.
- Pricing pressure is concentrated in two products: Acephate faces pressure in Brazil and Hexaconzole in Southeast Asia, where inventory levels are qualitatively understood to be high; the U.S. market offers much better pricing flexibility, with Europe following a similar pattern.
- Raw material tailwinds may not all flow to margin: While raw material and freight costs are trending down, in markets with inventory overhang or competitive pressure, the company may have to share those declines with customers to stay competitive, making blended margin a function of geographic mix.
- Formulations are the margin lever: Management expects international margins to gradually improve as the share of formulation business in exports increases; formulations currently represent roughly 20% of international revenue.
- Growth going forward will be volume-driven: With raw material prices cooling, realizations may trend lower, shifting the growth composition toward volumes rather than price.
S. Nagarajan: "As you would appreciate, the combination of the products that we sell and the markets where we sell, that is really the combination that can determine the level of pricing flexibility that we could have."
Margins: Holding the Line While Clearing Inventory
- EBITDA margin improved 30 bps YoY to 12.4%: The gain came from higher overall growth, but PBT margins declined because of higher depreciation and lower investment and other income.
- International margins absorbed the raw material shock: The quantum of price increases was not commensurate with raw material cost increases, squeezing international profitability; domestic margins were maintained through mix and pricing discipline.
- High-cost inventory liquidation is largely done: The company deliberately accepted lower margins to work down high-cost inventory, and management says it is in a much better position than three months ago, with that drag now behind.
- Percentage margins compress mechanically when raw materials spike: Management noted that when raw material costs rise sharply, percentage margins always come under pressure because the higher pricing sits in the denominator, even if absolute profit is maintained.
- Forward margin trajectory is hard to call: Commodity prices remain high and crop economics are favorable, but broader inflation, currency depreciation in customer markets affecting farmer affordability, and weather events like European droughts create confounding variables that make margin prediction difficult.
Sanjiv Lal: "More or less, we have tried to work down our high-cost inventory. So I think we are in a much better position today than what we were maybe three months back because we have had to take some lower margins, especially for liquidating some of the high-cost inventory that we were holding."
Working Capital & Receivables: Stress on Both Fronts
- Domestic collection days lengthened materially: The increase in outstanding receivables was more than proportionate to sales growth, driven by deficit rainfall in Eastern India hampering liquidation, excess rainfall in Western India leading to skipped sprays, and a moderation of payment incentives at the beginning of the year that has since been corrected.
- International receivables rose on a deliberate policy shift: The company stopped discounting receivables from one key international customer, producing a sizable one-time increase; a mix of customers with varying credit periods and relatively high Q2 export sales added to the effect. No international customers are overdue at this stage.
- Short-term borrowings bridged the gap: Interim debt was used to manage cash needs arising from the working capital stretch; management expects this may rise by another ₹50–100 crore by year-end but does not foresee a significant increase beyond that.
- No credit loss risk is anticipated: Management does not foresee any risks on receivables and is focused on reducing the outstanding position in Q3, with the Rabi season offering a hopeful catalyst for normalization.
Seeds Business: Restructuring Underway, More Pain Possible
- The vegetable seeds business is being scaled back and merged: After a review of persistent underperformance, the vegetable seeds operation will be folded into the field crop business as part of a broader restructuring.
- Inventory provisions are weighing on the P&L: The company took ₹25 crore in inventory provisions in H1, and management cautioned that additional provisions may be necessitated as the cost review continues through the year.
- Diggaz cotton hybrid is a bright spot: The newer launch saw sharp volume pickup, and the company is targeting a doubling of sales in the next Kharif season, though scaling will be gradual rather than dramatic.
- H2 will remain loss-making for Seeds: Q3 and Q4 are historically small and loss-making for the seeds business; the priority now is Kharif hybrid seed production and market development for a strong Kharif next year.
Strategic Initiatives: Building the Next Leg of Growth
- Contract manufacturing wins will take time to mature: The company finalized one contract manufacturing opportunity for a formulated product and one for an active material, both with new customers. Commercialization is expected during FY24, but meaningful revenue will take 2–3 years as customer registrations, including adding the Dahej-SEZ as a source, are completed.
- The new MPP plant commissions toward Q4: Revenue streams from the multi-purpose plant are expected to begin in FY24, scale through FY25, and reach meaningful levels only thereafter due to registration timelines.
- Local sourcing is reducing import dependence: The company now sources 100% of its requirement for two products locally; for two more important intermediates, it sources 20% locally for one and targets 80% for the other by year-end, both previously 100% imported.
- Brazil registrations are unlocking new formulations: Registration was obtained for a Metribuzin formulated product, already started, and for a formulated Acephate product, with business commencing now.
- PEKK plant restarting after a two-year shutdown: Shipments are expected to commence from Q4 FY2023 as orders begin to come back.
- Export share ambition is set at ~40% by FY26: The target is to be driven by manufacture-led exports including contract manufacturing, catalogue sales from the current portfolio, and new active ingredients commercialized starting FY24.
- ROCE ambition is high double-digits, but no timeline: Management aims to progressively improve ROCE as capacities get utilized, though only ~₹550 crore of the ~₹800 crore committed capex has been invested so far, with further investment still to come.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Business pickup | Higher reservoir levels and good soil moisture to aid Rabi season; remunerative global agri commodity prices to aid international business | H2 FY23 |
| PEKK shipments resume | Orders coming back; shipments to commence | Q4 FY23 |
| New CM contracts reach scale | Two contract manufacturing wins to generate meaningful revenue after customer registrations complete | 2–3 years |
| Local sourcing target | One intermediate to reach 80% local sourcing, up from 0% previously; another intermediate to reach 20% local sourcing | By year-end FY23 |
| Crop Nutrition growth | At least 20% growth targeted for the category | Current year (FY23) |
| Export revenue share | Exports to reach ~40% of Crop Protection revenue, driven by manufacture-led exports and new AIs | By FY26 |
| MPP revenue start | New multi-purpose plant commissioning; revenue streams to begin and scale thereafter | Commissioning Q4 FY23; revenue from FY24, scaling FY25+ |
| Seeds restructuring provisions | Additional inventory and other provisions may be necessitated as cost review continues | During FY23 |
| Interim debt | May require additional short-term borrowings; not expected to exceed ₹50–100 crore increase | By year-end FY23 |
| Diggaz cotton hybrid scaling | Targeting doubling of sales | Next Kharif season |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue | ₹951 cr, +31% YoY |
| Domestic business revenue | ₹608 cr, +18.2% YoY, volume growth in low single-digits |
| International business revenue growth | +67.4% YoY, driven by both volume and value |
| Seeds business revenue | ₹28 cr |
| EBITDA | ₹118 cr, vs ₹88 cr in Q2 FY22 |
| EBITDA margin | 12.4%, +30 bps YoY |
| Profit after tax | ₹71 cr, +26% YoY |
| Crop Nutrition revenue (FY22 full year) | ~₹145 cr, outlooking at least 20% growth in FY23 |
| Formulated products share of export business | ~20% |
| International business share of Crop Protection revenue | 33–35%, expected to reach ~40% by FY26 |
| Diggaz cotton hybrid packets sold | 1.7 lakh packets, vs 20,000 in previous year |
| Seeds business inventory provisions (H1 FY23) | ₹25 cr |
| Capex spent in H1 FY23 | ~₹100 cr, out of ₹250 cr planned for the year |
| Metribuzin revenue growth (H1 FY23 vs H1 FY22) | >60% |
| Pendimethalin revenue growth (H1 FY23 vs H1 FY22) | >20% |
| Acephate plant utilization | 100% |
| Pendimethalin plant utilization | ~90% |
| Pendimethalin capacity | ~5,000 tonnes per year |
| Metribuzin capacity | ~3,000 tonnes per year |
| International debtors days on hand | 30–40% higher vs previous year |
| PEKK shipments | Restarting in Q4 FY23, after a gap of 2 years |